C
38.20
3.40 (9.77%)
| Previous Close | 34.80 |
| Open | 35.69 |
| Volume | 6,635,245 |
| Avg. Volume (3M) | 1,223,319 |
| Market Cap | 4,025,200,128 |
| Price / Earnings (TTM) | 43.91 |
| Price / Earnings (Forward) | 38.02 |
| Price / Sales | 6.17 |
| Price / Book | 6.36 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | 19.55% |
| Operating Margin (TTM) | 2.17% |
| Diluted EPS (TTM) | 1.15 |
| Quarterly Revenue Growth (YOY) | 7.10% |
| Quarterly Earnings Growth (YOY) | -26.00% |
| Total Debt/Equity (MRQ) | 1.00% |
| Current Ratio (MRQ) | 3.07 |
| Operating Cash Flow (TTM) | 179.44 M |
| Levered Free Cash Flow (TTM) | 160.08 M |
| Return on Assets (TTM) | 9.18% |
| Return on Equity (TTM) | 21.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Corcept Therapeutics Incorporat | Bearish | Bearish |
AIStockmoo Score
1.5
| Analyst Consensus | 3.0 |
| Insider Activity | 0.0 |
| Price Volatility | 5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.49% |
| % Held by Institutions | 80.05% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 99.00 (Canaccord Genuity, 159.16%) | Buy |
| Median | 95.00 (148.69%) | |
| Low | 90.00 (HC Wainwright & Co., 135.60%) | Buy |
| Average | 94.67 (147.83%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 52.51 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 02 Jan 2026 | 99.00 (159.16%) | Buy | 38.20 |
| HC Wainwright & Co. | 02 Jan 2026 | 90.00 (135.60%) | Buy | 38.20 |
| 25 Nov 2025 | 145.00 (279.58%) | Buy | 80.28 | |
| UBS | 16 Dec 2025 | 95.00 (148.69%) | Hold | 81.12 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BELANOFF JOSEPH K | 83.59 | 83.59 | -306,846 | -25,649,257 |
| ROBB GARY CHARLES | - | 83.59 | -80,284 | -6,710,940 |
| Aggregate Net Quantity | -387,130 | |||
| Aggregate Net Value ($) | -32,360,197 | |||
| Aggregate Avg. Buy ($) | 83.59 | |||
| Aggregate Avg. Sell ($) | 83.59 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BELANOFF JOSEPH K | Officer | 24 Dec 2025 | Disposed (-) | 550,000 | 83.59 | 45,974,500 |
| BELANOFF JOSEPH K | Officer | 24 Dec 2025 | Acquired (+) | 243,154 | 83.59 | 20,325,243 |
| BELANOFF JOSEPH K | Officer | 24 Dec 2025 | Option execute | 550,000 | - | - |
| ROBB GARY CHARLES | Officer | 24 Dec 2025 | Disposed (-) | 80,284 | 83.59 | 6,710,940 |
| ROBB GARY CHARLES | Officer | 24 Dec 2025 | Option execute | 145,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |